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Association of genetic variants of methionine metabolism with
methotrexate-induced CNS white matter changes in patients with
primary CNS lymphoma
Abstract
Methotrexate (MTX) is an important anticancer drug and the most efficient chemotherapy component in
primary central nervous system lymphoma (PCNSL). A typical side effect of intravenous high-dose
MTX is the occurrence of confluent CNS white matter changes (WMC). Since MTX directly interferes
with methionine metabolism, we analyzed the impact of genetic variants of methionine metabolism on
the occurrence of WMC as a model of MTX toxicity. In a retrospective analysis of 68 PCNSL patients
treated with MTX-based polychemotherapy with (n=42) or without (n=26) intraventricular treatment,
ten genetic variants influencing methionine metabolism were analyzed. Pearson's Chi-square test and
multinominal regression analysis were used to define the relevance of these genetic variants for the
occurrence of WMC. In this patient sample, the occurrence of WMC was significantly predicted by the
TT genotype of methylenetetrahydrofolate reductase c.677C>T (chi(2)=8.67; p=0.013; df=2), the AA
genotype of methylenetetrahydrofolate reductase c.1298A>C (chi(2)=13.5; p=0.001; df=2) and the GG
genotype of transcobalamin 2 c.776C>G (chi(2)=19.73; p<0.001) in addition to male gender
(chi(2)=11.95; p=0.001). These data strengthen the hypothesis that MTX effects are influenced by
methionine metabolism which may offer new strategies to improve MTX-based therapies.
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Abstract 
Methotrexate (MTX) is an important anticancer drug and the most efficient chemotherapy 
component in primary central nervous system lymphoma (PCNSL). A typical side-effect of 
intravenous high-dose MTX is the occurrence of confluent CNS white matter changes (WMC). 
As MTX directly interferes with methionine metabolism, we aimed to analyze the impact of 
genetic variants of methionine metabolism on the occurrence of WMC as a model of MTX 
toxicity. In a retrospective analysis of 68 PCNSL patients treated with MTX-based 
polychemotherapy with (n=42) or without (n=26) intraventricular treatment, eleven genetic 
variants influencing methionine metabolism were analyzed. Pearson’s Chi-square test and 
multinominal regression analysis were used to define the relevance of these genetic variants for 
the occurrence of WMC. In this patient sample, the occurrence of WMC was significantly 
predicted by genotypes of methylenetetrahydrofolate reductase c.677C>T (χ2=8.67; p=0.013), 
methylenetetrahydrofolate reductase c.1298A>C (χ2=13.5; p=0.001) and transcobalamin 2 
c.776C>G (χ2=19.73; p<0.001) in addition to male gender (χ2=11.95; p=0.001). These data 
strengthen the hypothesis that MTX effects are influenced by methionine metabolism which may 
offer new strategies to improve MTX-based therapies.  
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Introduction 
The anticancer and anti-inflammatory drug methotrexate (MTX) is a competitive inhibitor of 
several enzymes involved in folate and methionine metabolism such as dihydrofolate reductase 
(DHFR), aminoimidazole carboxamide synthase, glycinamide ribonucleotide transformylase and 
thymidylate synthethase (TS).1,2 Manifestations of MTX-toxicity include nausea, mucositis, 
myelosuppression, and renal, liver and pulmonary dysfunction. Neurotoxicity of MTX may 
present with acute, subacute and chronic encephalopathy as well as with clinically asymptomatic 
subacute confluent white matter changes (WMC), which are diagnosed on T2 weighted MRI 
sequences.3 Response to MTX-based chemotherapy and manifestation of toxicity show a high 
inter-individual variability. It is therefore important to identify factors influencing MTX effects 
in order to improve treatment outcome.  
 
Uptake of folates into the cells occurs through organic bi-directional anion carriers like the 
reduced folate carrier 1 (RFC1) as well as through the unidirectionally folate receptors alpha and 
beta, that mediate folate uptake into cells via endocytosis. These receptors as well as several 
transporters that unidirectionally export folates from cells, are also involved in uptake and export 
of MTX.4 The intracellular DHFR-inhibiting effect of MTX leads to a depletion of 5,10-CH2-
FH4 and thereby to both an impairment of nucleic acid synthesis and of homocysteine 
remethylation via 5,10-methylenetetrahydrofolate reductase (MTHFR) and 5-
methyltetrahydrofolate-homocysteine S-methyltransferase (MTR). As this is the only pathway of 
homocysteine remethylation in the CNS, application of MTX can lead to a marked increase of 
neurotoxic homocysteine within the CNS and to a lack of S-adenosylmethionine (SAM), which 
is necessary for myelination within the CNS, neuronal membrane stability and 
neurotransmission.2,5-8.  
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MTX is the most efficient drug in the treatment of primary central nervous system lymphomas 
PCNSL,9 which account for 3% of all primary brain tumors in the United States (Central Brain 
Tumor Registry of the United States, 2004). Prognosis of PCNSL, which are highly aggressive 
tumors, is poor with a median survival of approximately two months in untreated patients. Brain 
irradiation, chemotherapy and combination of these result in a substantially improved 
survival.10,11 The “Bonn protocol” to treat PCNSL is a high-dose MTX (cycles 1, 2, 4 and 5) 
based systemic polychemotherapy regimen including alkylating agents, vinca-alkaloids and 
dexamethasone combined with intraventricular MTX, prednisolone, and ARA-C, which has 
resulted in a five-year-survival fraction of 75% in patients <60 years.12 
 
In a recent study we observed that the presence of at least one of the genotypes MTHFR 
c.677TT, MTR c.2756AG/GG or transcobalamin 2 (Tc2, transport protein of the MTR cofactor 
vitamin B12) c.776GG was associated with the occurrence of WMC in a sample of 42 MTX-
treated PCNSL patients, but we failed to identify a significant independent association of any of 
these genotypes with WMC.13 In the present study we extended the patient sample to 68 patients 
and analyzed a larger set of in total eight polymorphisms of methionine metabolism. Here, we 
identified three functional polymorphisms that independently predicted the occurrence of WMC.  
 
Patients and methods 
The study population consisted of 68 consecutive PCNSL patients (32 male, 36 female) of 
Caucasian origin, who had been treated in two prospective chemotherapy trials: Until December 
2002 treatment included intraventricular drug administration (MTX, prednisolone and Ara-C) 
(“original Bonn protocol”, n=42).12. Afterwards, patients were treated without intraventricular 
therapy (“modified Bonn protocol”, n=26; unpublished). Median age at diagnosis was 59 years 
(range 28 to 77).  
 5
 
Of the 68 patients, 55 completed therapy (six cycles of polychemotherapy), and all 68 underwent 
at least two cycles. MRI was carried out before initiation of therapy. The second MRI, which was 
used to define occurrence of WMC, was performed after two cycles of chemotherapy to assess 
treatment response as part of the trial protocol.12 None of the patients underwent brain irradiation 
prior to MRI assessment. WMC were defined as new, confluent and symmetrical hyperintense 
lesions of the supratentorial white matter detectable on FLAIR and T2-weighted images.3  
 
Genotyping was performed by amplification of genomic DNA applying polymerase chain 
reaction (PCR) and subsequent restriction enzyme digestion or by allele specific PCR, followed 
by agarosegel-electrophoresis. For analysis of the ATIC polymorphism c.347C>G.14, we used the 
PCR primers 5’-AGCTGTAAACCACATGAGTGG and 5’-AGGCAGAGGTTGCAGTCAGC 
with an annealing temperature of 61°. The PCR product of 471bp was digested with the 
restriction enzyme HpyCH4III (New England Biolabs, Frankfurt, Germany) resulting in 
fragments of 26bp, 96bp, 349bp for the G-allele, and 21bp, 26bp, 96bp, 328bp for the C-allele. 
The other PCR and restriction analysis conditions were essentially as described.15-22 Genetic 
analyses and correlations with WMC were done in a retrospective approach. Biochemical 
parameters like plasma levels of folate, vitamin B6 or vitamin B12, were not available. 
Diagnosis of WMC was independently made by the chairman of the subdivision of Neuro-
Oncology (US) and by the chairman of the subdivision of Neuro-Radiology (HU). For all 
patients, both made the same diagnosis (newly developed WMC after the 2nd cycle of 
chemotherapy, yes or no). Diagnosis of WMC was made blinded for the results from the genetic 
analyses and vice versa. Mix-up of asymptomatic WMXC with severe leukoencephalopathy in 
MRI-based diagnoses was unlikely, because leukoencephalopathies generally present different in 
MRI and develop later than the respective MRI was done.23  
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Nominal regression analysis (α=0.05) was used to test the independent predictive value of the 
covariables polymorphisms, age, gender, Karnofsky score before therapy, and application of 
intraventricular therapy (yes or no) on the incidence of WMC (definition given above) as 
endpoint. For the tested genotypes the Hardy-Weinberg equilibrium was calculated for all 
PCNSL patients together (with or without WMC) with a Chi2 goodness-of-fit-test (alpha=0.05). 
Informed written consent was obtained from all patients or their legal guardians. This study was 
approved by the local ethics committees. 
 
Results 
Of the 68 patients, one patient died after the 2nd cycle before MRI could be carried out, and 
suitable MRI studies from 2 further patients were not available for other reasons. Thus, a total of 
65 PCNSL patients were analyzed for the occurrence of WMC (Table 1). The Hardy-Weinberg 
equilibrium of the observed genotype frequencies was fulfilled for each genetic variant. The C-
allele of the rare polymorphism CBS c.833T>C (I278T) was not detected in this study’s sample, 
and this polymorphism was excluded from further analyses.  
 
Overall, 20 (31%) of the 65 patients showed clinically asymptomatic WMC, and 45 did not. In 
all 20 cases, WMC was detectable in the MRI after the 2nd cycle of therapy; no-one of the 55 
patients who completed the six cycles of therapy developed WMC later than after the 2nd cycle.  
In no patient, WMC occurred thereafter. Multivariate nominal regression analysis revealed that 
the occurrence of WMC was predicted by male gender (χ2=11.95; p=0.001; OR=2.54, 
CI95%=0.85-7.58). In addition, three genetic variants independently predicted the occurrence of 
WMC in our patient sample: MTHFR c677C>T (χ2=8.67; p=0.013; OR conferred by the TT 
genotype: 6.0, CI95%=1.32-27.2), MTHFR c.1298A>C (χ2=13.5; p=0.001; OR conferred by the 
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AA genotype: 6.00, CI95%=1.72-20.9) and Tc2 c.776C>G (χ2=19.7; p<0.001; OR conferred by 
the GG genotype: 2.15, CI95%=0.67-6.97). The DHFR c.594+59del19bp variant showed a 
significant prediction of WMC formation in nominal regression analysis (χ2=6.63; p=0.036), 
however, this result was due to an over-representation of heterozygous cases only, which is not 
plausible. Thus, this result must be disregarded if not confirmed in other studies. The 
polymorphism ATIC c.346C>G was associated with WMC for trend (χ2=4.97; p=0.083; OR 
conferred by the GG genotype: 3.5, CI95%=0.70-17.4) 
 
Discussion 
The antifolate MTX is an important anticancer drug. The understanding of mechanisms involved 
in MTX toxicity is important to improve MTX therapies. WMC represent signs of mild MTX-
induced neurotoxicity, which in its extreme variant may present as necrotising encephalopathy 
after intraventricular MTX application24 or as a dementing disease after combination of systemic 
MTX with whole brain radiotherapy.25 Using this model we aimed to analyze whether genetic 
variants of methionine metabolism modify the susceptibility to MTX toxicity. We cannot decide 
to what extend the results of our study may be transferred to different treatment protocols. 
 
Male gender was significantly associated with WMC. The methionine metabolism is influenced 
by endogenous steroids,26 which may provide an explanation for gender-specific differences of 
the WMC rates. In contrast to our data, Hoekstra and co-workers reported that MTX withdrawal 
as putative sign of side-effects was more frequent in female than in male patients treated with 
low-dose oral MTX (≥15mg/week).27 Speculatively, the impact of gender on MTX toxicity may 
differ between therapy regimens (long-term low-dose versus high-dose) and organs, however, 
gender-specific MTX effects and side-effects have not been clearly evaluated, so far.  
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We have previously reported preliminary data suggesting that a combined genotype of 
polymorphisms of methionine and folate metabolism may be associated with the occurrence of 
WMC in MTX-treated patients who carry at least one of the genotypes MTHFR c.677TT, MTR 
c.2756AG/GG or Tc2 c.776GG, but that study did not identify any significant independent 
association of one of these genotypes with WMC.13 In the present study we attempted to identify 
clinical and genetic risk factors for the formation of WMC in a larger series of PCNSL patients 
treated with high-dose MTX. In multivariate analysis, the Tc2 c.776C>G and the two MTHFR 
missense polymorphisms c.677C>T and c.1298A>C showed a significant association with the 
occurrence of WMC, and the missense polymorphism ATIC c.346C>G showed an association 
for trend.  
 
The MTHFR polymorphism c.677C>T (p.A222V) leads to a reduced MTHFR activity disposing 
a lower remethylation rate of homocysteine to methionine and, thus, to lower SAM 
concentrations and increased homocysteine levels (figure 1).16 The missense polymorphism Tc2 
c.776C>G (p.P259R) is known to alter the affinity of Tc2 to cobalamin also leading to a reduced 
remethylation of homocysteine to methionine.15,28,29 Thus, the T allele of MTHFR c.677C>T and 
the G-allele of Tc2 c.776C>G may both plausibly pronounce the homocysteine-increasing and 
the SAM-decreasing effect of MTX leading to a higher risk of MTX-induced WMC as observed 
in our study. Anecdotally, we have previously reported serial data on CSF analyses of four 
PCNSL patients treated with high-dose MTX showing that those two of four patients with the 
GG genotype of Tc2 c.776C>G had the lowest CSF levels of SAM. One of these Tc2 c.776GG 
carriers was the only one of those four patients who developed WMC.30 In that study we also 
reported that during MTX treatment, homocysteine CSF levels increased up to 17-fold in 
patients treated with intraventricular MTX. As we found that even slight elevations of 
homocysteine levels lead to neuronal dysfunction in cultured cells as well as in primary 
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neurons,13 the increase of neurotoxic homocysteine during MTX treatment is a possible 
mechanism of MTX neurotoxicity in addition to SAM-depletion. Polymorphisms of methionine 
metabolism may be relevant modifiers.  
 
Concerning the second genetic variant with significant influence on the occurrence of WMC in 
multivariate analysis, MTHFR c.1298A>C (p.E429A), we have shown that this polymorphism 
influences MTHFR activity in human fibroblasts (about 80% activity in CC fibroblasts as 
opposed to AA fibroblasts).31 However, the A-allele, which was associated with higher MTHFR 
activity in our as well as in other studies,32,31 was observed in association with WMC. This is in 
contrast to our hypothesis on elevated homocysteine and reduced SAM levels as reasons for 
MTX neurotoxicity. However, the MTHFR c.1298A>C and c.677C>T variants are in linkage 
disequilibrium, i.e. c.677T allele is linked to c.1298A33. Thus, an over-representation of c.677T 
alleles accounts for an over-representation of c.1298A alleles. The limited number of patients 
with different haplotypes in this series precludes the identification of a MTHFR 
c.677C>T;c.1298A>C haplotype predisposing to the development of WMC. Thus, we cannot 
decide whether the linkage disequilibrium with MTHFR c.677C>T or a different mechanism 
may explain the observed association of the wildtype A-allele of MTHFR c.1298A>C with 
WMC. 
 
The enzyme ATIC is involved in folate metabolism catalyzing the two final steps of purine 
synthesis. Previous studies did not observe any biological effect of the ATIC polymorphism 
c.346C>G (p.T116S),14 which showed an association with WMC for trend only. Thus, especially 
the effect of the ATIC polymorphism on the occurrence of WMC has to be retested in an 
independent patient sample.  
In summary, within the limitations of any association study, the present study supports the 
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hypothesis that methionine metabolism modifies MTX (neuro)toxicity. The manipulation of 
methionine metabolism, e.g. by supplementation of SAM (figure 1), may be a promising strategy 
to improve MTX tolerance. 
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Table 1. Factors predicting the incidence of white matter changes (WMC) 
therapy ivt + ivt –   regression 
WMC + (n=20) 0.70 0.30  
WMC – (n=45) 0.60 0.40  
χ2=0.652; p=0.420 
     
Age mean sd   
WMC + (n=20) 62.2 7.2  
WMC – (n=45) 55.2 13.0  
χ2=2.32; p=0.128 
     
Karnofsky mean sd   
WMC + (n=20) 69.1 16.4  
WMC – (n=45) 72.7 15.4  
χ2=0.011; p=0.917 
     
gender female male   
WMC + (n=20) 0.35 0.65  
WMC – (n=45) 0.58 0.42  
χ2=11.95; p=0.001 
     
ATIC  
c.346C>G 
CC CG GG  
WMC + (n=20) 0.48 0.33 0.19 
WMC – (n=45) 0.44 0.49 0.07 
χ2=4.97; p=0.083 
     
CBS  
c.844_845ins68 
del/del ins/del ins/ins  
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WMC + (n=20) 0.80 0.20 0 
WMC – (n=45) 0.78 0.22 0 
χ2=0.857; p=0.355 
     
DHFR 
c.594+59del19bp 
del/del ins/del ins/ins  
WMC + (n=20) 0.10 0.70 0.20 
WMC – (n=45) 0.23 0.41 0.36 
χ2=6.63; p=0.036 
     
MTHFR c.677C>T CC CT TT  
WMC + (n=20) 0.50 0.20 0.30 
WMC – (n=45) 0.53 0.40 0.07 
χ2=8.67; p=0.013 
     
MTHFR c.1298A>C AA AC CC  
WMC + (n=20) 0.80 0.10 0.10 
WMC – (n=45) 0.40 0.47 0.13 
χ2=13.5; p=0.001 
     
MTR c.2756A>G AA AG GG  
WMC + (n=20) 0.65 0.35 0 
WMC – (n=45) 0.67 0.29 0.04 
χ2=0.702; p=0.402 
     
RFC1 c.80G>A 0 1 2  
WMC + (n=20) 0.25 0.50 0.25 
WMC – (n=45) 0.32 0.39 0.30 
χ2=3.35; p=0.187 
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TC2 c.776C>G CC CG GG  
WMC + (n=20) 0.20 0.45 0.35 
WMC – (n=45) 0.33 0.47 0.20 
χ2=19.73; p<0.001 
     
TSER 28bp repeat 2/2 2/3 3/3  
WMC + (n=20) 0.19 0.33 0.48 
WMC – (n=45) 0.20 0.51 0.29 
χ2=3.193; p=0.203 
 
Nominal regression with all parameters as listed as covariables. Karnofsky: before therapy. sd: 
standard deviation. ivt: intraventricular therapy. WMC: white matter changes. For MTR, the AG 
and the GG genotype were pooled for multiple nominal regression analysis. Genetic analysis 
included the genetic variants 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase/inosine monophosphate cyclohydrolase (ATIC) c.346C>G (p.T116S; rs 
2372536), cystathionine beta-synthase (CBS) c.833T>C (missense mutation p.I278T; not 
detected in our study and not included in Table 1), CBS c.844_855ins68 (splice alteration 
affecting the transcript level; GenBank S78267.1), dihydrofolate reductase (DHFR) 
c.594+59del19bp (intronic deletion supposedly affecting the transcript level; GenBank 
NM_000791.3),  methylenetetrahydrofolate reductase (MTHFR) c.677C>T (missense mutation 
p.A222V; rs1801133) and MTHFR c.1298A>C (missense mutation p.E429A; rs1801131),  
methionine-homocysteine S-methyltransferase (MTR) c.2756A>G (missense mutation p.D919G; 
rs1805087), reduced folate carrier 1 (RFC1) c.80G>A (missense mutation p.R27H; rs1051266), 
transcobalamin 2 (Tc2) c.776C>G (missense mutation p.P259R; rs1801198), and the 28bp repeat 
of the thymidylate synthase (TYMS) enhancer region (TSER; 2 or 3 repeats; GenBank 
NM_001071).  
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Figure legend 
Figure 1 – Human methionine metabolism 
 
Activated methionine (S-adenosylmethionine, SAM) is the methyl group donor for numerous 
reactions. The degradation product of SAM is S-adenosylhomocysteine (SAH), which is 
hydrolysed to homocysteine by SAH-hydrolase. Homocysteine can be transsulfurated to 
cystathionine by the vitamin B6-dependent cystathionine beta-synthase (CBS), and subsequently, 
via the vitamin B6-dependent cystathionine gamma-lyase, to cysteine. Cysteine is essential for 
glutathione synthesis. Alternatively, homocysteine can be remethylated to methionine by 5-
methyltetrahydrofolate-homocysteine S-methyltransferase (MTR, also called methionine 
synthase). MTR requires methylcobalamin (a derivate of vitamin B12) and 5-
methyltetrahydrofolate (5-CH3-FH4) as cofactors. Transcobalamin 2 (Tc2) is the major 
transporter protein for cobalamin, 5-CH3-FH4 is synthesized from 5,10-
methylenetetrahydrofolate (5,10-CH2-FH4) by 5,10-methylenetetrahydrofolate reductase 
(MTHFR), and 5,10-CH2-FH4 is synthesized by dihydrofolate reductase (DHFR) in two 
subsequent steps from the folate pool. 5,10-CH2-FH4 is also needed for nucleic acid synthesis, in 
which thymidylate synthase (TYMS) and 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase/inosine monophosphate cyclohydrolase (ATIC)  
are involved. Thus, MTHFR activity regulates whether a one-carbon unit of tetrahydrofolate is 
utilized for methionine synthesis or for nucleic acid synthesis, and thus for DNA synthesis, 
stability and repair. 5,10-CH2-FH4 is regenerated from 5-CH3-FH4 by MTR during methionine 
synthesis.  
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